NASDAQ
25.18USD
+1.12 (+4.66%)
We have scored 7 news catalysts on Kestra Medical Technologies, Ltd. (KMTS) over the past 12 months. The biggest single-day move next to one of them came Jan 4, 2026, when KMTS closed −8.0%: “Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 6.1% – Here’s Why”. Coverage across the window leans positive (average ticker sentiment +0.16). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.5B
P/E
—
EPS
—
Beta
0.62
52W range
17.34-30
Day range
21.56–25.44
Open
21.82
Prev close
24.06
Volume
887.6K
Avg volume
349.3K
Dividend
0.00
IPO
2025-03-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kestra Medical Technologies, Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KMTS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
